4 ms·
That depends entirely on how much they are paid to delay. A successful pay to delay settlement can be more profitable for the generic than entering the market.
by s1artibartfast 8y ago
That depends entirely on how much they are paid to delay. A successful pay to delay settlement can be more profitable for the generic than entering the market. That is to say, it is more profitable to share revenue from a monopoly than race to the bottom.
A classic example is GSK and TEVA with Lamictal. GSK priced the original drug at $465/dose with $1.5 billion in sales. Teva's Generic was $14/dose. TEVA happily agreed to be paid by GSK because if TEVA had won in court, entered the market, and captured 100%, they would only bring in 50 million a year
https://www.fiercepharma.com/regulatory/more-scotus-fallout-appeals-court-revives-lamictal-pay-for-delay-fight-against-gsk-teva https://www.fiercepharma.com/regulatory/more-scotus-fallout-...
- refurb 8y agoDo you have another source? The one you shared is light on details. I'm not sure why TEVA would price at $14/dose at launch - most exclusive generics price at ~95% of the branded therapy, then drop once other generic entries happen. If the TEVA generic were to capture 50% of the market over 6 months, that's $600M+ in revenue, not $50M.